Prognostic significance of the Gustave Roussy immune (GRIm) score in cancer patients: a meta-analysis

作者全名："Sun, Ke-Xin; Xu, Ru-Qin; Rong, Huan; Pang, Hua-Yang; Xiang, Ting-Xiu"

作者地址："[Sun, Ke-Xin; Xu, Ru-Qin; Xiang, Ting-Xiu] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing, Peoples R China; [Rong, Huan; Pang, Hua-Yang; Xiang, Ting-Xiu] Chongqing Univ, Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis & I, Chongqing, Peoples R China; [Pang, Hua-Yang; Xiang, Ting-Xiu] 181 Hanyu Rd, Chongqing 400030, Peoples R China"

通信作者："Pang, HY; Xiang, TX (通讯作者)，181 Hanyu Rd, Chongqing 400030, Peoples R China."

来源：ANNALS OF MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:001085776200001

JCR分区：Q1

影响因子：4.9

年份：2023

卷号：55

期号：2

开始页：　

结束页：　

文献类型：Article

关键词：Cancers; Gustave Roussy immune score; survival outcomes; meta-analysis

摘要："Background: The prognostic value of the Gustave Roussy immune (GRIm) score in cancer patients has been widely reported but remains inconsistent. The aim of this study is to systematically investigate the relationship between the GRIm score and survival outcomes in cancer patients. Methods: Relevant literature was identified using electronic databases including Web of Science, PubMed, and Embase from the inception to March 2023. The primary endpoints were long-term oncological outcomes. Subgroup analysis and sensitivity analysis were conducted during the meta-analysis. Results: Fifteen studies (20 cohorts) including 4997 cancer patients were enrolled. The combined results revealed that patients in the high GRIm group had a deteriorated overall survival (HR = 2.07 95%CI: 1.73-2.48; p < 0.0001; I-2 = 62%) and progression-free survival (HR = 1.42; 95%CI: 1.22-1.66; p < 0.0001; I-2 = 36%). The prognostic values of GRIm on overall survival and progression-free survival were observed across various tumour types and tumour stages. Sensitivity analysis supported the stability and reliability of the above results. Conclusion: Our evidence suggested that the GRIm score could be a valuable prognostic marker in cancer patients, which can be used by clinicians to stratify patients and formulate individualized treatment plans."

基金机构："Natural Science Foundation of Chongqing [CSTC2021jscx-gksb-N0023, CSTC2022jxjl0234]"

基金资助正文：This study was funded by Natural Science Foundation of Chongqing (CSTC2021jscx-gksb-N0023; CSTC2022jxjl0234).